Editorial

Current Pharmaceutical Design

Volumn 20, Issue 42, 2014, Pages 6511-6512

  Pavelic, Jasminka ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AROMATASE INHIBITOR; CURCUMIN; CYTOSTATIC AGENT; IMMUNOTOXIN; MICRORNA; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PHOSPHOTRANSFERASE INHIBITOR; RIBOSOME INACTIVATING PROTEIN; TOLL LIKE RECEPTOR 3; UNTRANSLATED RNA;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CARCINOGENESIS; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; METASTASIS INHIBITION; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE C MYC; OXIDATIVE STRESS; PANCREAS CANCER; POSTMENOPAUSE; SIDE EFFECT; SYSTEMIC THERAPY; TUMOR CELL; TUMOR MICROENVIRONMENT; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS;

EID: 84911475477     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140826154834     Document Type: Editorial

References (14)

1. Fillat C, Maliandi MV, Mato-Berciano A, Alemany R. Combining oncolytic virotherapy and cytotoxic therapies to fight cancer. Curr Pharm Des 2014; 20(42): 6513-21.
2. Schaap-Nutt A, Thyssen DA, David W. Drell DW, Entschladen F. Anti-metastatics: an overview of drug candidates in current pipelines. Curr Pharm Des 2014; 20(42): 6522-8.
3. Milkovic L, Siems W, Siems R, Zarkovic N. Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des 2014; 20(42): 6529-42.
4. Huang H, Weng H, Zhou H, Lianghu Qu L. Attacking c-Myc: targeted and combined therapies for cancer. Curr Pharm Des 2014; 20(42): 6543-54.
5. Braicu C, Catana C, Calin GA, Berindan-Neagoe I. Fighting cancer: ncRNA combined therapy could be a future option. Curr Pharm Des 2014; 20(42): 6565-74.
6. Dembic Z. Pharmaco-therapeutic challenges in cancer biology with focus on the immune-system related risk factors. Curr Pharm Des 2014; 20(42): 6652-9.
7. Matijevic Glavan T, Pavelic J. The exploitation of Toll-like receptor 3 signaling in cancer therapy. Curr Pharm Des 2014; 20(42): 6555-64.
8. Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AMH. Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance. Curr Pharm Des 2014; 20(42): 6575-83.
9. Gilabert-Oriol R, Weng A, von Mallinckrodt B, Melzig MF, Fuchs H, Thakur M. Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy. Curr Pharm Des 2014; 20(42): 6584-643.
10. Gall Troselj K, Novak Kujundzic R. Curcumin in combined cancer therapy. Curr Pharm Des 2014; 20(42): 6682-96.
11. Reguera P, Madariaga A, Grande E. A comprehensive review of poorly differentiated neuroendocrine carcinomas (pdNECs): a niche to find novel opportunities. Curr Pharm Des 2014; 20(42): 6644-51.
12. Yang Q, Chen LS, Gandhi V. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Curr Pharm Des 2014; 20(42): 6670-81.
13. Melisi D, Calvetti L, Frizziero M, Tortora G. Pancreatic cancer: systemic combination therapies for a heterogeneous disease. Curr Pharm Des 2014; 20(42): 6660-69.
14. Cavalcante L, Kelsen DP, Yu KH. Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue. Curr Pharm Des 2014; 20(42): 6697-701.